NGNE
Neurogene Inc.
$27.71
+0.10
(+0.36%)
Mkt Cap
437.87M
Volume
83,651
52W Range
14.65-37.266
Sector
Healthcare
Beta
2.08
EPS (TTM)
-5.03
P/E Ratio
-4.83
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 925,000 | 0 | 0 | 0 | 0 | 0 | 25.00M | 0 | 0 | 0 | 0 |
| Net Income | (90.35M) | (75.14M) | (36.32M) | (55.19M) | (50.52M) | (33.28M) | (69.44M) | (31.59M) | (50.18M) | (37.00M) | (21.86M) | (23.82M) |
| EPS | -4.24 | -4.28 | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 |
| Free Cash Flow | (78.36M) | (71.41M) | (51.74M) | (55.05M) | (64.77M) | (26.79M) | (16.27M) | (31.63M) | (45.21M) | (30.94M) | N/A | N/A |
| FCF / Share | -3.70 | -4.07 | -4.03 | -4.29 | -1.18 | -0.52 | -0.60 | -1.34 | -1.93 | -1.64 | N/A | N/A |
| Operating CF | (77.17M) | (70.60M) | (51.42M) | (52.82M) | (46.40M) | (24.57M) | (15.39M) | (31.58M) | (44.72M) | (30.23M) | N/A | N/A |
| Total Assets | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M | 210.52M | 147.02M | 77.62M | 110.33M | 154.38M | N/A | N/A |
| Total Debt | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M | 12.12M | 1.21M | 5,999 | 32,999 | 47,000 | N/A | N/A |
| Cash & Equiv | 103.84M | 136.59M | 148.21M | 82.02M | 70.54M | 192.56M | 143.09M | 76.93M | 52.03M | 32.30M | N/A | N/A |
| Book Value | 264.89M | 310.38M | 186.02M | 98.63M | (91.88M) | 191.22M | 141.69M | 72.67M | 98.89M | 144.66M | N/A | N/A |
| Return on Equity | -0.34 | -0.24 | -0.20 | -0.56 | N/A | -0.17 | -0.49 | -0.43 | -0.51 | -0.26 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 925,000 | 0 | 0 | 0 | 0 |
| Net Income | (30.93M) | (24.73M) | (20.95M) | (22.02M) | (22.65M) | (19.51M) | (20.22M) | (18.49M) | (16.92M) | 2.38M | (14.58M) | (11.86M) |
| EPS | -1.39 | -1.60 | -0.99 | -1.05 | -1.08 | -1.31 | -1.19 | -1.09 | -1.00 | -1.21 | -0.41 | -0.21 |
| Free Cash Flow | (26.40M) | (16.79M) | (19.81M) | (19.61M) | (21.55M) | (17.61M) | (15.73M) | (16.35M) | (21.71M) | (29.28M) | (11.65M) | (9.41M) |
| FCF / Share | -1.18 | -1.08 | -0.94 | -0.93 | -1.03 | -1.19 | -0.93 | -0.97 | -1.28 | -2.28 | -1.05 | -0.17 |
| Operating CF | (26.12M) | (16.67M) | (19.68M) | (19.46M) | (20.77M) | (17.50M) | (15.56M) | (15.89M) | (21.65M) | (29.52M) | (11.57M) | (9.33M) |
| Total Assets | 263.14M | 289.18M | 287.83M | 297.32M | 315.30M | 335.73M | 164.12M | 179.82M | 195.35M | 222.57M | 89.59M | 85.79M |
| Total Debt | 9.13M | 9.89M | 11.27M | 12.85M | 13.54M | 12.43M | 14.53M | 13.79M | 14.41M | 16.25M | 11.47M | 4.39M |
| Cash & Equiv | 124.16M | 103.84M | 71.00M | 58.81M | 70.77M | 136.59M | 66.63M | 111.03M | 150.14M | 148.21M | 25.23M | 59.05M |
| Book Value | 237.78M | 264.89M | 265.54M | 273.25M | 291.80M | 310.38M | 137.41M | 155.01M | 170.78M | 186.02M | 75.23M | (169.05M) |
| Return on Equity | -0.13 | -0.09 | -0.08 | -0.08 | -0.08 | -0.06 | -0.15 | -0.12 | -0.10 | 0.01 | -0.19 | N/A |
NGNE News
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference
Neurogene to Participate in Stifel 2026 Virtual CNS Forum